title: [Medical treatment of juvenile idiopathic arthritis].
abstract: Although etiology of juvenile idiopathic arthritis (JIA) is currently not known, better understanding of immunologic pathways of inflammation and the development of new therapies with biologic agents have remarkably improved the treatment of JIA. However, approximately 30% of the patients with JIA do not seem to response adequately to conventional anti-rheumatic drugs but the arthritis runs a continuously active course and may lead to the evolution of erosions. Such patients benefit from biologic agents, of which the longest clinical experience comes from anti-TNF therapies. Molecules targeting IL-1, IL-6 and B- and T-lymphocytes are also used in the treatment of severe JIA.
authors.affiliation: KYS, Lasten- ja nuorten klinikka ja Itä-Suomen Yliopisto.
authors.forename: Liisa
authors.initials: L
authors.lastname: Kröger
authors.forename: Paula
authors.initials: P
authors.lastname: Vähäsalo
authors.forename: Pirjo
authors.initials: P
authors.lastname: Tynjälä
authors.forename: Kristiina
authors.initials: K
authors.lastname: Aalto
authors.forename: Hanna
authors.initials: H
authors.lastname: Säilä
authors.forename: Merja
authors.initials: M
authors.lastname: Malin
authors.forename: Anne
authors.initials: A
authors.lastname: Putto-Laurila
authors.forename: Pekka
authors.initials: P
authors.lastname: Lahdenne
mesh_terms: D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001171:Arthritis, Juvenile / Q000188:drug therapy* / Q000276:immunology; D018450:Disease Progression; D006801:Humans; D007375:Interleukin-1 / Q000037:antagonists & inhibitors; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D000093242:Interleukin-6 Inhibitors
chemical_list: D018501:Antirheumatic Agents; D007375:Interleukin-1; D014409:Tumor Necrosis Factor-alpha; D000093242:Interleukin-6 Inhibitors